Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 462-468

  Botta Orfila, Teresa ^a   Tolosa, Eduard ^a,b   Gelpi, Ellen ^a   Sànchez Pla, Alex ^c,d   Martí, Maria José ^a,b   Valldeoriola, Francesc ^a,b   Fernández, Manel ^a   Carmona, Francesc ^c   Ezquerra, Mario ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Denervation; Gene expression; Long term potentiation; LRRK2; Microarray; Parkinson's Disease; Putamen; Quantitative real time PCR; Synaptic plasticity; Synaptic transmission

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CALCIUM; DOPAMINE; GENOMIC RNA; GLYCINE; LEUCINE RICH REPEAT KINASE 2; SERINE;

ARTICLE; ASYMPTOMATIC DISEASE; CALCIUM SIGNALING; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; EXON; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LONG TERM POTENTIATION; MUTATIONAL ANALYSIS; NERVE CELL PLASTICITY; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PUTAMEN; SIGNAL TRANSDUCTION;

DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; PUTAMEN; SIGNAL TRANSDUCTION;

EID: 81955167469     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.033     Document Type: Article

References (62)

1. Adams J.R., van Netten H., Schulzer M., Mak E., Mckenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
2. Alegre-Abarrategui J., Christian H., Lufino M.M., Mutihac R., Venda L.L., Ansorge O., Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
3. Berger K., Przedborski S., Cadet J.L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull. 1991, 26:301-307.
4. Bonifati V. Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. Eur. J. Hum. Genet. 2006, 14:1061-1062.
5. Bourtchuladze R., Frenguelli B., Blendie J., Cioffi D., Schütz G., Silva A.J. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell 1994, 79:59-68.
6. Canales R.G., Luo Y., Willey J.C., Austermiller B., Barbacioru C.C., Boysen C., Hunkapiller K., Jensen R.V., Knight C.R., Lee K.Y., Ma Y., Magsodi B., Papallo A., Peters E.H., Poulter K., Ruppel P.L., Samaha R.R., Shi L., Yang W., Zhang L., Goodsaid F.M. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol. 2006, 24:1115-1122.
7. DART-PCR 1.0 software Last access. http://www.gene-quantification.de.
8. Database for Annotation Visualization and integrated discovery (DAVID) Last access. http://david.abcc.ncifcrf.gov.
9. Di Filippo M., Picconi B., Tantucci M., Ghiglieri V., Bagetta V., Sgobio C., Tozzi A., Parnetti L., Calabresi P. Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory. Behav. Brain Res. 2009, 199:108-118.
10. Draghici S., Khatri P., Tarca A.L., Amin K., Done A., Voichita C., Georgescu C., Romero R. A systems biology approach for pathway level analysis. Genome Res. 2007, 17:W1537-W1545. 10.1101/gr.6202607.
11. Edgar R., Domrachev M., Lash A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30:207-210.
12. Gaig C., Ezquerra M., Marti M.J., Muñoz E., Valldeoriola F., Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch. Neurol. 2006, 63:377-382.
13. Gaig C., Martí M.J., Ezquerra M., Rey M.J., Cardozo A., Tolosa E. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J. Neurol. Neurosurg. Psychiatry 2007, 778:626-628.
14. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 2006, 59:714-719.
15. GenEx Pro4.3.6.software Last access. http://www.gene-quantification.de.
16. Goldwurm S., Zini M., Mariani L., Tesei S., Miceli R., Sironi F., Clementi M., Bonifati V., Pezzoli G. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007, 68:1141-1143.
17. Grünblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., Li J., Ravid R., Roggendorf W., Riederer P., Youdim M.B. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 2004, 111:1543-1573.
18. Häbig K., Walter M., Poths S., Riess O., Bonin M. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 2008, 9:83-94.
19. Han B.S., Iacovitti L., Katano T., Hattori N., Seol W., Kim K.S. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci. Lett. 2008, 442:190-194.
20. Haugarvoll K., Rademakers R., Kachergus J.M., Nuytemans K., Ross O.A., Gibson J.M., Tan E.K., Gaig C., Tolosa E., Goldwurm S., Guidi M., Riboldazzi G., Brown L., Walter U., Benecke R., Berg D., Gasser T., Theuns J., Pals P., Cras P., De Deyn P.P., Engelborghs S., Pickut B., Uitti R.J., Foroud T., Nichols W.C., Hagenah J., Klein C., Samii A., Zabetian C.P., Bonifati V., Van Broeckhoven C., Farrer M.J., Wszolek Z.K. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008, 70:1456-1460.
21. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W., Internacional LRRK2 Consortium Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
22. Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. QBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007, 8:R19. 10.1186/gb-2007-8-2-r19.
23. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007, 1155:208-219.
24. Ho C.C., Rideout H.J., Ribe E., Troy C.M., Dauer W.T. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 2009, 29:1011-1016.
25. Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
26. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
27. Hucka M., Finney A., Sauro H.M., Bolouri H., Doyle J.C., Kitano H., Arkin A.P., Bornstein B.J., Bray D., Cornish-Bowden A., Cuellar A.A., Dronov S., Gilles E.D., Ginkel M., Gor V., Goryanin I.I., Hedley W.J., Hodgman T.C., Hofmeyr J.H., Hunter P.J., Juty N.S., Kasberger J.L., Kremling A., Kummer U., Le Novère N., Loew L.M., Lucio D., Mendes P., Minch E., Mjolsness E.D., Nakayama Y., Nelson M.R., Nielsen P.F., Sakurada T., Schaff J.C., Shapiro B.E., Shimizu T.S., Spence H.D., Stelling J., Takahashi K., Tomita M., Wagner J., Wang J., Forum S.B.M.L. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 2003, 19:524-531.
28. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
29. Impey S., Mark M., Villacres E.C., Poser S., Chavkin C., Storm D.R. Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 1996, 16:973-982.
30. Ingenuity Pathways Analysis software (IPA) Last access. http://www.ingenuity.com.
31. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
32. Isaias I.U., Benti R., Goldwurm S., Zini M., Cilia R., Gerundini P., Di Fonzo A., Bonifati V., Pezzoli G., Antonini A. Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Mov. Disord. 2006, 21:1144-1147.
33. Kapur K., Xing Y., Ouyang Z., Wong W.H. Exon arrays provide accurate assessments of gene expression. Genome Biol. 2007, 8:R82.
34. Khatri P., Bhavsar P., Bawa G., Draghici S. Onto-tools: an ensemble of web-accessible, ontology-based tools for the functional design and interpretation of high-throughput gene expression experiments. Nucleic Acids Res. 2004, 32:W449-W456. 10.1093/nar/gkh409.
35. Khatri P., Voichita C., Kattan K., Ansari N., Khatri A., Georgescu C., Tarca A.L., Draghici S. Onto-Tools: new additions and improvements in 2006. Nucleic Acids Res. 2007, 35:W206-W211.
36. Lesage S., Dürr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., Pollak P., Brice A. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J. Med. 2006, 354:422-423. French Parkinson's Disease Genetics Study Group.
37. Lesage S., Belarbi S., Troiano A., Condroyer C., Hecham N., Pollak P., Lohman E., Benhassine T., Ysmail-Dahlouk F., Dürr A., Tazir M., Brice A. Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?. Neurology 2008, 71:1550-1552. French Parkinson's Disease Genetics Study Group.
38. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder G.A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
39. Martí-Massó J.F., Ruiz-Martínez J., Bolaño M.J., Ruiz I., Gorostidi A., Moreno F., Ferrer I., López de Munain A. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov. Disord. 2009, 24:1998-2001.
40. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
41. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 2002, 326:155-158.
42. Melrose H., Lincoln S., Tyndall G., Dickson D., Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794.
43. Miwa H., Kubo T., Suzuki A., Nishi K., Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 2005, 380:93-98.
44. Mortiboys H., Johansen K.K., Aasly J.O., Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75:2017-2020.
45. Murphy D., Segal M. Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc. Natl Acad. Sci. USA 1997, 94:1482-1487.
46. Mutez E., Larvor L., Leprêtre F., Mouroux V., Hamalek D., Kerckaert J.P., Pérez-Tur J., Waucquier N., Vanbesien-Mailliot C., Duflot A., Devos D., Defebvre L., Kreisler A., Frigard B., Destée A., Chartier-Harlin M.C. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol. Aging 2010, 10.1016/j.neurobiolaging.2009.10.016.
47. Nishioka K., Kefi M., Jasinska-Myga B., Wider C., Vilariño-Güell C., Ross O.A., Heckman M.G., Middleton L.T., Ishihara-Paul L., Gibson R.A., Amouri R., Ben Yahmed S., Ben Sassi S., Zouari M., El Euch G., Farrer M.J., Hentati F. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:391-395.
48. Onto-Tools software Last access. http://vortex.cs.wayne.edu/projects.htm.
49. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., Lipton R.B., Soto-Valencia J., Risch N., Bressman S.B. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J. Med. 2006, 354:424-425.
50. Picconi B., Pisani A., Centonze D., Battaglia G., Storto M., Nicoletti F., Bernardi G., Calabresi P. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 2002, 125:2635-2645.
51. Picconi B., Pisani A., Barone I., Bonsi P., Centonze D., Bernardi G., Calabresi P. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 2005, 5:779-783.
52. Picconi B., Paillé V., Ghiglieri V., Bagetta V., Barone I., Lindgren H.S., Bernardi G., Angela Cenci M., Calabresi P. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis. 2008, 29:327-335.
53. Simunovic F., Yi M., Wang Y., Macey L., Brown L.T., Krichevsky A.M., Andersen S.L., Stephens R.M., Benes F.M., Sonntag K.C. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009, 132:1795-1809.
54. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3.
55. Sutherland G.T., Matigian N.A., Chalk A.M., Anderson M.J., Silburn P.A., Mackay-Sim A., Wells C.A., Mellick G.D. A cross-study transcriptional analysis of Parkinson's disease. PLoS One 2009, 4:e4955.
56. Tan E.K. The role of common genetic risk variants in Parkinson disease. Clin. Genet. 2007, 72:387-393.
57. Thaler A., Ash E., Gan-Or Z., Orr-Urtreger A., Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J. Neural Transm. 2009, 116:1473-1482.
58. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. RESEARCH0034.
59. Vogt I.R., Lees A.J., Evert B.O., Klockgether T., Bonin M., Wüllner U. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp. Neurol. 2006, 199:465-478.
60. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 2005, 102:16842-16847.
61. Yin J.C.P., Wallach J.S., Del Vecchio M., Wilder E.L., Zhou H., Quinn W.G., Tully T. Induction of a dominant negative CREB transgene specifically blocks long-term memory in Drosophila. Cell 1994, 79:49-58.
62. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carvajal I.C., Vieregge P., Asmas F., Müller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.